GlassScriptPhysician profile
Rujuta Saksena
NPI 1851522197
$6,896.87
in general payments reported to CMS, 2019-2025
29 companies · $444 in 2025
The $444 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $504 · 2020: $1,216 · 2021: $29.75 · 2022: $4,600 · 2023: $51.18 · 2024: $51.33 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $409 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.78 |
| Education | $137.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $4,598.47 | 2022-2025 | Monoferric |
| Puma Biotechnology, INC. | $1,000.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $260.45 | 2019-2025 | |
| Gilead Sciences, INC. | $139.74 | 2019-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $124.77 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Lilly USA, LLC | $100.00 | 2019-2024 | Jaypirca, Verzenio |
| E.R. Squibb & Sons, L.L.C. | $75.27 | 2019-2025 | Opdualag, Krazati |
| Amgen INC. | $59.03 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $56.35 | 2020 | |
| Genentech USA, INC. | $52.13 | 2019-2025 | Itovebi |
| Takeda Pharmaceuticals U.S.A., INC. | $50.32 | 2019-2020 | |
| Pfizer INC. | $37.91 | 2019 | |
| Janssen Biotech, INC. | $33.50 | 2020-2025 | Darzalex |
| Pharmacyclics LLC, An Abbvie Company | $30.76 | 2019-2023 | Imbruvica, Epkinly |
| Abbvie INC. | $30.42 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $29.90 | 2019 | |
| Celgene Corporation | $27.75 | 2019 | |
| Eisai INC. | $19.74 | 2025 | |
| Glaxosmithkline, LLC. | $18.89 | 2025 | Zejula, Jemperli |
| Genzyme Corporation | $17.98 | 2025 | |
| Adaptive Biotechnologies Corporation | $16.12 | 2025 | Clonoseq |
| Daiichi Sankyo INC. | $15.93 | 2020 | |
| Roche Diagnostics Corporation | $15.35 | 2019 | |
| Incyte Corporation | $14.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.77 | 2019 | |
| Kite Pharma, INC. | $14.57 | 2020 | |
| Emd Serono, INC. | $14.47 | 2025 | |
| Astellas Pharma US INC | $14.37 | 2025 | Vyloy |
| Astrazeneca Pharmaceuticals LP | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rujuta Saksena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.